For patients with brain cancer, the benefits of surgery
followed by targeted radiation therapy are well known.
However, physicians have had to weigh their treatment
choices with important considerations. Side effects
associated with external beam radiation and complicated
treatment planning and execution of brain brachytherapy
have left physicians with limited options.
Working in conjunction with leading neurosurgeons and
radiation oncologists, Cytyc Surgical Products has
developed a patented cancer treatment device, the
GliaSite Radiation Therapy System (RTS), that is
designed to deliver site-specific internal radiation
therapy and minimize radiation exposure to healthy
brain tissue.
Designed to be placed inside the tumor resection
cavity, the GliaSite RTS delivers radiation with
Iotrex® Radiotherapy Solution, a proprietary 125I
radiation source placed inside a balloon catheter.
Targeted tissue receives a high dose of radiation,
while exposure to healthy tissue is minimized.
Treatment is administered for 3 to 7 days.
Learn more
about GliaSite RTS
|
